Is there a risk of melanoma with erectile dysfunction drugs?

Last Updated on

November 01, 2017 – According to the watch list of the American Food & Drug Administration (FDA) for drugs with possible safety issues from January to March 2016,

the FDA was looking at the possible link between various drugs in the phosphodiesterase-5 (PDE-5) inhibitors class and melanoma as a serious adverse effect. Drugs in this class include Sildenafil (Viagra), Tadalafil (Cialis), Vardenafil (Levitra), Vardenafil (Staxyn), and Avanafil (Stendra), all for the indication of erectile dysfunction. Moreover, Tadalafil (Cialis) is also prescribed sometimes when doctors see the signs and symptoms of benign prostatic hyperplasia (BPH). Likewise, two other PDE-5 inhibitors, Sildenafil (Revatio) and Tadalafil (Adcirca) are FDA-approved for the treatment of pulmonary arterial hypertension (PAH).

To date, there has not been any status update from the FDA on their investigation about this possible malignant melanoma adverse effect of these PDE-5 drugs. But during 2017 thus far, there have been a few medical journal articles published regarding the safety issue of whether PDE-5 inhibitor drugs might cause or promote skin cancer, especially melanoma, which can be fatal.

The latest review article on the issue appeared online in the journal Sexual Medicine Reviews on October 12, 2017 and was entitled “Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction”. From this article’s abstract, there are two relevant points presented by these medical researchers:

  • There appears to be an association between Phosphodiesterase type 5 (PDE-5) inhibitor use and melanoma but the absence of a mechanism of causation raises doubt that the association is cause and effect.
  • Evidence on increased rates of melanoma and prostate cancer recurrence is weak and controversial.

 

A second article was published online in the Oncotarget Journal in April 2017, entitled in start with “Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review”. The abstract of this article, which sets forth the findings of some medical researchers in China, states that:

Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03–1.21, I2 = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.

Lastly, the article  “Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis”, written by researchers affiliated with American and Chinese medical institutions and published by the Journal of the American Academy of Dermatology in September 2017 states that:

Five observational studies were included. Compared with PDE-5 inhibitor nonuse, PDE-5 inhibitor use was slightly but significantly associated with an increased risk for development of melanoma (OR, 1.12; 95% CI, 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95% CI, 1.09-1.19) but not squamous cell carcinoma. For melanoma risk, none of the prespecified factors (dose of PDE5 inhibitor, study design, and study region) significantly affected the results (P > .05). Our sensitivity analysis confirmed the stability of the results. The conclusion was that use of PDE-5 inhibitors may be associated with a slightly increased risk for development of melanoma and basal cell carcinoma but not squamous cell carcinoma. However, further large well-conducted prospective studies with adequate adjustment for potential confounders are required for confirmation.

Indeed, judging from these investigations, it is no surprise that an association of a risk of melanoma with erectile dysfunction drug use remains controversial. And it comes with no surprise that we still look forward to eventually hearing from the FDA concerning their investigations of this important drug safety issue. Nevertheless, the issue leaves patients who take these drugs with considerable uncertainty.

____________

Tags: , , , , , , , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Descendants of early Europeans and Africans in US carry Native American genetic legacy September 19, 2019
    Many people in the U.S. do not belong to Native American communities but still carry bits of Native American DNA, inherited from European and African ancestors who had children with indigenous individuals during colonization and settlement. In a new study published 19th September in PLOS Genetics, Andrew Conley of the Georgia Institute of Technology and […]
  • IGF1 gene is essential to adult tendon growth, animal study shows September 19, 2019
    Tendon injuries are among the most common injuries seen in athletes at all levels, from weekend warriors to professional basketball players. For those who rupture their tendons, returning to the same level of physical activity they enjoyed before the injury is rare.
  • Researchers create new protocol to improve gene therapy tool production September 19, 2019
    A method to create a faster and lower cost alternative for a gene therapy tool has been developed by Boston University School of Medicine (BUSM) researchers.
  • Genetic variants with possible positive implications for lifestyle September 19, 2019
    A German and British research team lead by Technical University of Munich (TUM) has examined the interplay between genetics, cardiovascular disease and educational attainment in a major population study. Genetic variants which had been linked to educational attainment in other studies were observed in the subjects. The researchers found that these variants also had implications […]
  • Scientists develop new methodology to genetically modify lab mice and human cells September 19, 2019
    A team led by Cedars-Sinai has designed a rapid method to genetically alter laboratory mice and then used this method to produce personalized animal models of pediatric glioma, an aggressive type of malignant brain cancer in children.
Top